Anixa Biosciences Advances Breast Cancer Vaccine with New Patent Allowance Notification

Anixa Biosciences Receives Notice of Patent Allowance for Breast Cancer Vaccine Technology

San Jose, California - 9th April 2025
Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology firm dedicated to cancer treatment and prevention, has recently announced a key milestone in its breast cancer vaccine development. The U.S. Patent and Trademark Office (USPTO) has granted a Notice of Allowance for a patent that encapsulates critical advancements in the company's innovative breast cancer vaccine technology. This patent, alongside other related patents, has been exclusively licensed to Anixa by the prestigious Cleveland Clinic.

The newly allowed patent will expand the range of immunogenic compositions that Anixa utilizes within its breast cancer vaccine framework. These immunogenic compositions, integral to the vaccine's efficacy, are designed to bolster the human immune response against breast cancer cells. Specifically, the patent focuses on methods for immunizing patients via the administration of a composition that includes the human α-lactalbumin protein, which is naturally present in breast tissues during lactation. Notably, this protein is also expressed in certain breast cancers, making it a prime target for immunoprevention strategies that aim to combat this challenging disease at an early stage.

Dr. Amit Kumar, who serves as the Chairman and CEO of Anixa Biosciences, expressed enthusiasm regarding the patent's allowance, stating, "This patent not only enhances our intellectual property portfolio but also underscores the innovative nature of our breast cancer vaccine. Our repertoire of intellectual property includes several patents that have already been issued, alongside those that are currently pending, across both U.S. and international territories."

Overview of Anixa Biosciences

Anixa Biosciences is positioned at the forefront of clinical-stage biotechnology with a primary focus on developing novel therapeutic solutions to prevent and treat cancer. The company's therapeutic portfolio includes an ovarian cancer immunotherapy program, which is being developed in collaboration with Moffitt Cancer Center, utilizing a pioneering CAR-T technology referred to as chimeric endocrine receptor-T cell (CER-T) technology. Additionally, Anixa's vaccine portfolio, developed in partnership with the Cleveland Clinic, incorporates strategies aimed at treating and preventing both breast and ovarian cancer. Other initiatives are also underway to create vaccines targeting high-incidence malignancies such as lung, colon, and prostate cancer.

Anixa's vaccine technologies are particularly noteworthy as they focus on immunizing against "retired" proteins that have shown to be present in specific cancer forms. These innovative vaccine strategies, developed by experts at the Cleveland Clinic, have been licensed to Anixa, which will subsequently divert royalties and commercialization revenue to the Clinic from these vaccine technologies.

The uniqueness of Anixa's business model lies in its strategic collaborations with leading research institutions, which span all stages of development. This enables the company to constantly explore and incorporate cutting-edge technologies across complementary fields for future growth and commercialization opportunities.

For further information about Anixa Biosciences and its groundbreaking work in cancer research and vaccine development, please visit www.anixa.com or connect with the company on various platforms such as Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

It's important to highlight that certain statements within this announcement may be considered forward-looking as defined by the Private Securities Litigation Reform Act of 1995. These statements, which encompass expectations about future events and results, are inherently uncertain and carry risks and uncertainties. The company encourages investors to be cautious and avoid placing undue reliance on these projections, as actual outcomes may diverge from expectations due to unforeseen changes and factors beyond Anixa’s control.

For inquiries, please contact:
Mike Catelani
President, COO, and CFO
Email: [email protected]
Phone: 408-708-9808